INSP

Analyst Note: Inspire Medical Systems, Inc. (INSP)

Date: 2026-06-13 Current Price: $42.61

1. Structural Readiness

• State: Forming. The price action is currently consolidating above the structural support level, but the breakout signal has not yet fired.
• Aggressive/Pre-Breakout Entry: Not recommended as a standalone signal; the setup is currently in the "forming" phase.
• Breakout Level: Not yet established; requires price to close above the current resistance structure.
• Current Price: $42.61.
• Extension: Not applicable (price is not in an extended breakout phase).
• ATR Context: Current ATR is 5.5% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural setups, suggesting sufficient momentum for a potential move but requiring careful position sizing.

2. Thesis Layer

This is a TACTICAL, setup-led name. As of 2026-06-13, there is no named secular thesis driving the immediate setup. The investment case must be judged strictly on the quality of the technical structure (the forming coil) and the underlying business fundamentals provided in the evidence. No macro or thematic thesis should be invented to support the trade; the conviction rests on the alignment of management guidance, operational progress, and the structural price action.

3. Business Overview

Inspire Medical Systems, Inc. operates as a medical technology enterprise focused on the development and commercialization of advanced, minimally invasive therapies for patients diagnosed with moderate to severe Obstructive Sleep Apnea (OSA).

• Product & Indication: The company's proprietary Inspire system is the first FDA, EU MDR, and Japan PMDA-approved neurostimulation technology for this indication. It is indicated for patients who do not have significant central sleep apnea or complete concentric collapse of the airway.
• Market Reach & Penetration: As of March 31, 2026, the company has treated over 135,000 patients since inception. The sales force consists of 284 U.S. sales territories and 288 field clinical representatives.
• Financial Performance & Guidance:
• Revenue: For the quarter ended March 31, 2026, revenue was $204.6 million, an increase of 1.6% year-over-year.
• Full-Year Outlook: Management has revised the full-year 2026 revenue outlook to a range of $825 million to $875 million.
• Margin Profile: Gross margin increased to 86.5% in Q1 2026 (up from 84.7%), driven by a favorable sales mix of the higher-margin Inspire V system.
• Headwinds: Management explicitly cites adverse impacts from coding/reimbursement uncertainty and the new WISeR requirements in six states as factors that impacted Q1 revenue and are expected to continue impacting revenue for the remainder of 2026.
• Future Expectations: Management expects sequential improvement in both revenue and adjusted operating income from Q2 through the back half of the year, with Q4 anticipated to have the highest levels.
• Clinical & Competitive Landscape:
• Clinical Data: Long-term data (2+ years) demonstrates significantly lower odds of stroke, myocardial infarction, atrial fibrillation, and hospitalization for the Inspire cohort compared to controls.
• Competition: The company notes the FDA approval of tirzepatide (Zepbound) for OSA in 2024 as a competitive development, though Inspire remains the only approved neurostimulation therapy.
• Reimbursement: Positive coverage policies are secured with major commercial payors (over 300 million covered lives). Country-wide reimbursement exists in Germany, the Netherlands, Switzerland, France, Belgium, the UK, and Japan.
• Regulatory Pipeline: A new CPT code is expected to become effective on January 1, 2028, if approved.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Rationale: The company demonstrates high gross margins (86.5%), a growing installed base (135k+ patients), and a clear path to sequential operational improvement as identified by management. The business model is supported by strong clinical data and broad commercial reimbursement.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.90 for FY1 and $1.28 for FY2.
• Conviction Stack:
• Thesis Strength: Moderate. The lack of a named secular thesis limits the "narrative" upside, but the tactical setup is supported by solid fundamentals.
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm the revenue guidance, margin expansion, and operational headwinds.
• Structural Quality: Moderate. The setup is "forming," which historically has a ~69% breakout probability, but it is not yet confirmed. The high ATR (5.5%) suggests the market is pricing in volatility, which is favorable for a breakout but requires a tight stop.
• Rerating Potential: Dependent on the resolution of the WISeR/coding headwinds and the successful execution of the sequential improvement guidance.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• Breakout Confirmation: The setup is currently "forming," meaning the breakout has not fired. The specific price level for the breakout is not defined.
• Impact of Zepbound: While mentioned as a competitor, the specific quantitative impact of tirzepatide on Inspire's market share in 2026 is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management revised full-year revenue guidance to $825M-$875M with expectations of sequential improvement; Gross margin expanded to 86.5% driven by Inspire V mix; Clinical data shows significantly lower odds of major adverse cardiac events. Key risks: WISeR requirements and coding uncertainty continue to adversely impact revenue through 2026; Setup is in "forming" state with no confirmed breakout; New CPT code not effective until 2028, leaving near-term reimbursement headwinds unresolved. Sizing hint: Position size should reflect the "forming" status and high ATR; treat as a partial position until breakout confirmation. Expected path: Management expects sequential revenue and operating income improvement from Q2 through Q4, with Q4 being the strongest quarter; price action likely to consolidate before a potential breakout if guidance is met. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).